TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6794406

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 31116313

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 60
Study: 28466803

Group type: EXPERIMENTAL
Intervention: ENTAS 2 intra-rater reliability in dichotomy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 intra-rater reliability in grading
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 intra-rater reliability for damage evaluations
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T1 in dichotomy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T1 in grading
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T2 in dichotomy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T2 in grading
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability for damage evaluation at T1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability for damage evaluation at T2
Number of subjects: 47
Study: 27307996

Group type: EXPERIMENTAL
Intervention: Web-based tool for patients with CKD
Number of subjects: 264
Study: 24915210

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin ointment applied twice daily for 5 days before surgery
Number of subjects: 1697

Group type: COMPARATOR
Intervention: Nasal povidone-iodine solution applied twice into each nostril within 2 hours of surgical incision
Number of subjects: 1697
Study: 22561227

Group type: EXPERIMENTAL
Intervention: Innovative landmarks for subclavian vein cannulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional method for subclavian vein cannulation
Number of subjects: 0
Study: 19996720

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard Clinical Case Management
Number of subjects: 124
Study: 17365095

Group type: EXPERIMENTAL
Intervention: Phonological representation tasks
Number of subjects: 26
Study: 15119889

Group type: EXPERIMENTAL
Intervention: Emdogain enamel matrix proteins
Number of subjects: 8

Group type: COMPARATOR
Intervention: Surgical debridement alone (Control)
Number of subjects: 8
Study: 11477342

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (dose adjusted for renal function)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 9667249

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with dose adjustments based on toxicity.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF) administered to the subsequent 29 patients on all cycles.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC)
Number of subjects: 45
Study: 8092339

Group type: EXPERIMENTAL
Intervention: Naltrexone, 50 mg p.o.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3289507

Group type: EXPERIMENTAL
Intervention: 2 ppm NO2 gas for 1 hr
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 18
Study: 29300098

Group type: EXPERIMENTAL
Intervention: Online workplace mental health intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 196
Study: 28281235

Group type: EXPERIMENTAL
Intervention: Stratafix™ 2/0‐Ethicon (S-group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vicryl® 2/0‐Ethicon (V-group)
Number of subjects: 200
Study: 25947167

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) - 10 sessions, 30 minutes each, 2-10 Hz, intensity by tolerance, twice per week
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 34
Study: 23357545

Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAA) 6.7 g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Total amino acids as present in whey (Control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAA)
Number of subjects: 15
Study: 21258926

Group type: EXPERIMENTAL
Intervention: Anterolateral minimally invasive approach (ALMI, n=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Modified direct-lateral approach (mDL, n=19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard access (control for overweight group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard access (control for older patient group)
Number of subjects: 39
Study: 19764169

Group type: EXPERIMENTAL
Intervention: MLS‐MLR paradigm
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional MLR paradigm
Number of subjects: 10
Study: 17806038

Group type: EXPERIMENTAL
Intervention: Single-hole nipple units
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cross-cut nipple units
Number of subjects: 20
Study: 15448117

Group type: COMPARATOR
Intervention: Insertion of microdialysis catheters
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Repetitive low‐force exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control study (rest)
Number of subjects: 6
Study: 12061999

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment including lipid lowering drugs (52%), beta-blockers (50%), antiplatelet drugs (87%), ACE inhibitors (32%), nitrates (52%), calcium antagonists (31%), oral anticoagulants (8%)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Patients hospitalized during follow-up
Number of subjects: 618
Study: 9691642

Group type: EXPERIMENTAL
Intervention: Intracervical application of 0.5 mg dinoprostone gel
Number of subjects: 85
Study: 8591941

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg single dose
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 2746645

Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional cognitive strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructional sets supporting preferred coping style
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 195328

Group type: EXPERIMENTAL
Intervention: Regimen I: 3 months of INH + RMP (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Regimen II: 3 months of INH + SM + EMB (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Regimen I
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Regimen II
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 276
Study: 31691018

Group type: EXPERIMENTAL
Intervention: p-synephrine (3 mg kg-1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo (cellulose)
Number of subjects: 14
Study: 31096476

Group type: EXPERIMENTAL
Intervention: Thyroid disease group (both hyperthyroidism and hypothyroidism)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperthyroidism subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothyroidism subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroid disease patients without comorbidity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyroid disease group
Number of subjects: 0
Study: 28291262

Group type: EXPERIMENTAL
Intervention: Bumetanide (0.5, 1.0 or 2.0 mg twice daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 25477074

Group type: EXPERIMENTAL
Intervention: NFB + TAU
Number of subjects: 71

Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 71
Study: 23668330

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RPostC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 21078615

Group type: EXPERIMENTAL
Intervention: ARC1779 (83 and 250 nmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: abciximab (100 nmol/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19156121

Group type: EXPERIMENTAL
Intervention: Memantine (M) 5 mg daily for 1 week, then 10 mg daily for 1 week, then 15 mg daily for 1 week, then 20 mg daily from the 4th week
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no memantine)
Number of subjects: 15
Study: 16820073

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 4 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 8 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 12 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 16 weeks
Number of subjects: 120
Study: 12669393

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single fraction radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wide-field hemibody irradiation or systemic administration of radioisotopes
Number of subjects: 0
Study: 11783142

Group type: EXPERIMENTAL
Intervention: Baoyuan Qiangshen Capsule No. II (BYQS) combined with Lotensin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Essential amino acid combined with Lotensin
Number of subjects: 60
Study: 7557097

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 0
Study: 2196622

Group type: COMPARATOR
Intervention: Nefazodone (100 mg to 200 mg daily)
Number of subjects: 0
Study: 490852

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 31177325

Group type: EXPERIMENTAL
Intervention: Low-pass-filtered Word Stress Pattern (WSP-LPF) test
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sentence test with adaptive randomized roving level (STARR) test
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 36
Study: 28880941

Group type: EXPERIMENTAL
Intervention: One-day educational program for health workers in intravenous treatment
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics in nursing homes
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Intravenous fluids in nursing homes
Number of subjects: 330
Study: 24861418

Group type: EXPERIMENTAL
Intervention: Free reflective, fluorescent vests provided to 90 drivers in the intervention arm.
Number of subjects: 180

Group type: COMPARATOR
Intervention: No vests provided to 90 drivers in the control arm.
Number of subjects: 180
Study: 21817118

Group type: EXPERIMENTAL
Intervention: CVD risk factor screening program
Number of subjects: 118
Study: 19640363

Group type: EXPERIMENTAL
Intervention: Market capsule formulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Market suspension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clinical trial suspension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All formulations (market suspension, clinical trial suspension, market capsule)
Number of subjects: 24
Study: 17635595

Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg twice daily for 6 days
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 15288975

Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl 0.15%
Number of subjects: 1131

Group type: COMPARATOR
Intervention: timolol maleate 0.5%
Number of subjects: 1131

Group type: COMPARATOR
Intervention: betaxolol hydrochloride 0.5%
Number of subjects: 1131
Study: 12200522

Group type: EXPERIMENTAL
Intervention: Bronchial asthma patients during exacerbations (n=24)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Pneumonia patients at onset of illness (n=52)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IPF patients (n=21)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Bronchial asthma patients after 3 weeks of treatment with oral glucocorticoids (n=20)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Pneumonia patients after 3 weeks with clinical improvement (n=20)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of CRP with Hb-CO in pneumonia patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of CRP with Hb-CO in IPF patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of Hb-CO with FEV(1) in bronchial asthma patients after 3 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of exhaled CO with Hb-CO concentrations (n=33)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Normal control subjects (n=34)
Number of subjects: 151
Study: 9866667

Group type: EXPERIMENTAL
Intervention: Mupirocin cream applied topically 3 times daily
Number of subjects: 706

Group type: COMPARATOR
Intervention: Oral cephalexin given 4 times daily
Number of subjects: 706
Study: 7622767

Group type: EXPERIMENTAL
Intervention: 0.05 mg/m2 IFN-gamma treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ionomycin plus phorbol ester stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 16
Study: 2646083

Group type: EXPERIMENTAL
Intervention: Valtrac biofragmentable anastomotic ring (BAR)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Conventional suture techniques
Number of subjects: 438

Group type: COMPARATOR
Intervention: Stapling techniques
Number of subjects: 438
Study: 32041

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg i.v.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bunitrolol (10 mg i.v.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oxprenolol (10 mg i.v.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 33
Study: 31683183

Group type: EXPERIMENTAL
Intervention: Burn group (real upper limb burn injury)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simulated group (elbow flexed at 90° with a bandage)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal arm swing)
Number of subjects: 30
Study: 31672132

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 μg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28233921

Group type: EXPERIMENTAL
Intervention: Bio‐psychosocial Intervention (BPSI) coping skills class
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of cancer and follow‐up care (SOC)
Number of subjects: 120
Study: 25725940

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with dehydrated egg white
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23823951

Group type: EXPERIMENTAL
Intervention: Bioresorbable plates
Number of subjects: 69

Group type: COMPARATOR
Intervention: Titanium plates
Number of subjects: 69
Study: 21859559

Group type: EXPERIMENTAL
Intervention: PHY906
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PHY906 with irinotecan, 5‐fluorouracil (5‐FU), and leucovorin (LV)
Number of subjects: 0
Study: 19476594

Group type: EXPERIMENTAL
Intervention: Deity Yoga meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Presence meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (resting or performing other visuospatial tasks)
Number of subjects: 0
Study: 17874238

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16872529

Group type: EXPERIMENTAL
Intervention: Insecticide-treated clothes (ITCs)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 198
Study: 12589447

Group type: EXPERIMENTAL
Intervention: Far-outside group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Far-inside group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Near group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Internal-focus control group
Number of subjects: 3
Study: 10523747

Group type: EXPERIMENTAL
Intervention: Compliance measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical models for compliance data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated measures data on compliance and response
Number of subjects: 0
Study: 8694355

Group type: EXPERIMENTAL
Intervention: Local anesthetic (0.5% bupivacaine with epinephrine) after surgery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthetic (0.5% bupivacaine with epinephrine) before surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (20 ml 0.9% saline)
Number of subjects: 120
Study: 1683880

Group type: EXPERIMENTAL
Intervention: Stress management program based on the arousal‐attribution stress model
Number of subjects: 76
Study: 6755389

Group type: EXPERIMENTAL
Intervention: m‐Amsa (200 mg/m2 x 5 days) with Ara‐C (200 mg/m2 x 5 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: m‐Amsa (200 mg/m2 x 5 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: m‐Amsa (120 mg/m2 x 7 days) with Ara‐C (200 mg/m2 x 5 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: m‐Amsa (high doses)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: m‐Amsa (high doses) with Ara‐C (high doses)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Previous high doses of anthracyclins
Number of subjects: 91
Study: 30499637

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 48
Study: 28095813

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation augmented with cognitive behaviour therapy (CBT)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation augmented with cognitive remediation (CR)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 148
Study: 26051510

Group type: EXPERIMENTAL
Intervention: Adherence to WCRF/AICR recommendations (low, moderate, high)
Number of subjects: 275
Study: 23416514

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (PI) for 15 seconds
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (PI) for 30 seconds or more
Number of subjects: 131

Group type: COMPARATOR
Intervention: Lid speculum placement
Number of subjects: 131
Study: 21285135

Group type: EXPERIMENTAL
Intervention: E-learning group (n=106)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (n=105)
Number of subjects: 211
Study: 18635693

Group type: EXPERIMENTAL
Intervention: MDMA (1.6 mg/kg b.wt.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 17873500

Group type: EXPERIMENTAL
Intervention: Local anesthetics with adrenaline
Number of subjects: 39

Group type: COMPARATOR
Intervention: Local anesthetics without adrenaline
Number of subjects: 39
Study: 15326236

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days, followed by 10 mg/day as per clinician's judgment)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 290
Study: 11561261

Group type: EXPERIMENTAL
Intervention: Group I (air-buffered injections, n = 25)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group II (conventional injections, n = 19)
Number of subjects: 44
Study: 9626821

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 23
Study: 7946492

Group type: EXPERIMENTAL
Intervention: Linkworker intervention (encouragement and explanations about breast screening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no visits)
Number of subjects: 0
Study: 2884547

Group type: EXPERIMENTAL
Intervention: Clorazepate
Number of subjects: 18
Study: 31736381

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg oral daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional treatment (no drug)
Number of subjects: 28
Study: 31789961

Group type: EXPERIMENTAL
Intervention: Training according to Comfort Theory
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study: 30665435

Group type: EXPERIMENTAL
Intervention: Cross-sectoral and multimodal intervention for preventing delirium
Number of subjects: 1500
Study: 27285965

Group type: EXPERIMENTAL
Intervention: Fp MDPI 25 µg
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fp MDPI 50 µg
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fp MDPI 100 µg
Number of subjects: 622

Group type: COMPARATOR
Intervention: Fp DPI 100 µg
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 622
Study: 25972254

Group type: EXPERIMENTAL
Intervention: Hydrus Microstent with cataract surgery (CS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cataract surgery (CS) alone
Number of subjects: 100
Study: 23507227

Group type: EXPERIMENTAL
Intervention: Folic acid (800 μg) and vitamin B(12) (1000 μg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 21300255

Group type: EXPERIMENTAL
Intervention: Corticotomy-facilitated orthodontics
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no corticotomy)
Number of subjects: 13
Study: 19338157

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Xuefu Zhuyu Capsule (XFZYC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy alone (Control)
Number of subjects: 60
Study: 18043171

Group type: EXPERIMENTAL
Intervention: Topical indomethacin eyedrops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 16
Study: 15138424

Group type: EXPERIMENTAL
Intervention: TCRFTA treatment (3 tongue treatments)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TCRFTA treatment (2 additional tongue and palate treatments)
Number of subjects: 26
Study: 12101577

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Visual-analog laser procedure (WHO)
Number of subjects: 266